Biotech Values

[BTH]

I don't know about that.

There are a lot of examples of where KOLs are representative of outcomes. For instance, if you can get a vibe from the KOLs about what trials are exciting and which experimental drugs are being more enrolled rapidly, I think you can extrapolate that they (KOLs and physicians) are seeing promising results and want their patients enrolled. I think you can also assume that if docs aren't interested in having their patients enrolled in a trial, it's probably because others docs have seen limited results of efficacy and there are other more promising trials instead.